Skip to main
  1. Stocks
  2. LifeStance Health Group
  3. Forecast
LFST

LFST Stock Forecast & Price Target

LFST Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

LifeStance Health Gr is well positioned for sustained growth because its core outpatient mental health platform still has significant share gains ahead, with less than 5% share in most markets and presence in only about half of the 150 largest U.S. geographies. The company’s recent quarter showed strong fundamentals, including revenue of $455.9 million, 25.3% growth, adjusted EBITDA of $68.4 million, and a roughly 15% margin, supported by flat-to-up clinician productivity, 17% visit growth, and 7% higher revenue per visit. Its specialty care opportunity adds further upside through higher-acuity treatments like Spravato and TMS, while strong outcomes, internal patient referrals, and disciplined cost management support margin expansion and a durable earnings trajectory.

Bears say

LifeStance Health Gr is pressured by heavy reimbursement dependence, as UnitedHealthcare and Elevance Health together represented 29% of FY25 revenue, so any rate cuts, network exclusions, or contract losses could quickly impair results. Its outlook is further constrained by intense competition for clinicians, which can raise labor costs and limit growth if retention weakens, while patient volumes remain vulnerable to economic stress and insurance coverage losses. Although Specialty Care and Spravato offer growth potential, adoption is slowed by clinician training, qualification hurdles, and reimbursement economics that already make some geographies unviable, reducing near-term operating leverage.

LFST has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LifeStance Health Group and is not a guaranteed prediction by Public.com or investment advice.

LFST Analyst Forecast & Price Prediction

Get the latest LFST stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in LFST

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LifeStance Health Group (LFST) Forecast

Analysts have given LFST a Buy based on their latest research and market trends.

According to 7 analysts, LFST has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LifeStance Health Group (LFST)


LFST Analyst Forecast & Price Prediction

Get the latest LFST stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in LFST

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover LFST stock data and trends